Overview

• Anne Wojcicki proposed buying all outstanding shares at $0.40 each, an 11% premium over April's stock price.
• The company's stock has plummeted 78% over the past year, currently trading at $0.38 per share.
• 23andMe's revenue dropped 30% year-over-year, with significant declines in demand for DNA testing kits.
• The board's special committee plans to explore alternative transactions if no improved offer is made.
• 23andMe has faced challenges including a major data breach and struggles to achieve profitability.